医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

NuGEN Technologies Launches “Sharing Experiences and Applications in Science” (SEAS) Institute

2016年03月08日 AM12:00
このエントリーをはてなブックマークに追加


 

SAN CARLOS, Calif.

NuGEN Technologies, Inc. today announced the launch of the “Sharing Experiences and Applications in Sciences” (SEAS) Institute, the company’s platform for supporting and spotlighting the work of innovative scientists.

“This industry-first program provides an active environment for scientists to communicate, connect, and drive their research forward,” said Elizabeth Hutt, CEO of NuGEN. “As the leading provider of transformative technology addressing challenging sample types, we are ideally positioned to support scientists working on understanding disease to help change lives.”

The SEAS Institute enables scientists to share application-focused research studies and knowledge via industry conferences, webinars and white papers. Individuals that choose to participate (referred to as “SEAS Leaders”) can connect with their peers and gain visibility within the scientific community for their new approaches and advances. SEAS Leaders can choose from Bronze, Silver, and Gold levels of participation with each level offering benefits/remuneration to match their level of participation. In addition, SEAS Leaders can benefit from the increased awareness of their work to potentially secure grant money.

To find out more about becoming a SEAS Leader and the associated benefits, contact NuGEN at: SEAS@nugen.com

About NuGEN Technologies, Inc.

NuGEN Technologies, Inc. is a rapidly-growing, privately-held company that provides innovative products and systems used to prepare biologic samples for targeted genomic analysis. Founded in 2000 and based in San Carlos, CA, NuGEN has long been at the cutting edge of genomic technology, with accurate, cost-effective reagent kits for even the most challenging sample types. NuGEN products are used in more than 1000 leading life science institutes and in diagnostic and pharmaceutical companies in 40 countries. To learn more about NuGEN visit www.nugen.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160307005366/en/

CONTACT

NuGEN Technologies, Inc.
Carol Short, 650-590-3002
media@nugen.com

同じカテゴリーの記事 

  • ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
  • PROTEINA Initiates Global Clinical Validation Project with Emory University School of Medicine, USA
  • AriBio 获得欧洲药品管理局对AR1001治疗阿尔茨海默病3期临床试验(POLARIS-AD)的授权
  • AriBio Receives EMA Phase 3 Clinical Trial Authorisation for AR1001 in Treatment of Alzheimer’s Disease (POLARIS-AD)
  • ReNAgadeセラピューティクス、GanNA Bioと糖鎖生物学に対するコミットメントを継続